FDA accepts Merck's application on allergy treatment; Arena finally cleared by DEA to sell Belviq; Zalicus gets $25M funding deal;

@FierceBiotech: Nimbus Discovery announced agreement with Shire focused on small molecule treatments for rare genetic diseases. Release | Follow @FierceBiotech

@JohnCFierce: Painful to watch Vivus ($VVUS) scratching out sales for its weight drug. It's not built to market a drug like that. More | Follow @JohnCFierce

@RyanMFierce: Pfizer opts to keep running Accelrys software in its labs. Article | Follow @RyanMFierce

> The FDA has accepted Merck's ($MRK) application for a new ragweed treatment. The pharma giant partnered with ALK-Abello A/S on the treatment. Story

> The DEA has finally provided a Schedule IV designation for Arena's ($ARNA) weight drug Belviq, allowing the biotech to finally begin selling the treatment next month. Story

> Zalicus has snagged a $25 million funding commitment from Lincoln Park Capital. Release

> Actelion ($ATLN) has received a green light to proceed with its study of a new PAH drug, which could go on to become its third therapy for that indication. Report

Medical Device News

@FierceMedDev: FDA warns of criminals hocking stolen Covidien stapler reloads. More | Follow @FierceMedDev

@MarkHFierce: Biotronik won FDA approval for ICD/CRT-D devices, keeping it in the global race to unveil new products in the space. Story | Follow @MarkHFierce

 @DamianFierce: Stan Musial rises from the grave and takes a job at a specialty pharma outfit. Amazing, really. Release | Follow @DamianFierce

> FDA warns of criminals hocking stolen Covidien stapler reloads. Report

> ArthroCare's Q1 numbers come in flat. Article

> Good Start Genetics raises $28M for carrier Dx. News

Pharma News

@FiercePharma: India's own drugmakers are turned off their home market by gov't policy. For them, it's price caps. More | Follow @FiercePharma

@EricPFierce: Rapidly growing Sagent takes control of FDA approved China plant that it is ready to produce products. Article | Follow @EricPFierce

> U.S. Judge lashes out at FDA over its Plan B manuver. Story

> The pharma spin-offs have just begun, bankers figure. News

> GSK taps 'independent' experts to control trial-data access. More

Drug Delivery News

@MichaelGFierce: Frederick National Lab leads nanotech boom with cancer drug delivery. Report | Follow @MichaelGFierce

> 'Buckyball' capsule lets researchers steer drugs to target. Article

> Math model could choose most effective drug delivery nanoparticle. Story

> Langer's Kala touts positive results for topical wet AMD treatment. Report

> 'Smart' insulin nanoparticle controls blood sugar levels for up to 10 days. More

And Finally… Investigators at the Duke Cancer Institute have shed new light on what causes resistance the breast cancer drug lapatanib. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.